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5-hydroxytryptamine (5-HT) is derived from the essential amino acid L-tryptophan.
Although the compound has been studied extensively for its neuronal handling and
synaptic actions, serotonin 5-HT receptors can be found extra-synaptically and not
only in neurons but in many types of mammalian cells, inside and outside the central
nervous system (CNS). In sharp contrast, glutamate (Glu) and ATP are better known as
metabolism-related molecules, but they also are neurotransmitters, and their receptors
are expressed on almost any type of cell inside and outside the nervous system.
Whereas 5-hydroxytryptamine and Glu are key regulators of the immune system, ATP
actions are more general. 5-hydroxytryptamine, ATP and Glu act through both G protein-
coupled receptors (GPCRs), and ionotropic receptors, i.e., ligand gated ion channels.
These are the three examples of neurotransmitters whose actions as holistic regulatory
molecules are briefly put into perspective here.
Keywords: serotonin, adenosine receptors, purinergic signaling, P2 receptors, immune system, heart, COVID-19,
inflammatory bowel disease
INTRODUCTION
Neurotransmitters like dopamine or serotonin are more known for their actions in the central
nervous system (CNS). However, they act both in the CNS and in the periphery as regulators of
multiple functions and are key in maintaining whole body homeostasis. Recent studies suggest
a dopamine link between the gut and the CNS that is likely mediated by cells of the immune
system (see Franco et al., 2021 for review). Lymphocytes and other cells of the myeloid lineage
express many receptors for neurotransmitters: dopamine, serotonin, glutamate, etc. It seems that
the immune system has evolved in parallel to the nervous system and that the same molecules
regulate their functioning. Even the immunological synapse, constituted by the dendritic/antigen-
presenting cells and the lymphocyte, is very similar to the canonical synapse established between
two neurons or between a neuron and a myocyte (neuromuscular junction). A detailed account
of the novel aspects of every neurotransmitter is out of the scope of the present article. We have
decided to put into perspective three examples with their analogies and differences, namely 5-
hydroxytryptamine (5-HT), glutamate (Glu) and ATP. Glu and ATP share their involvement in
cell’s metabolism. 5-HT and Glu share their ability to regulate events of the immune system: from
Frontiers in Cell and Developmental Biology | www.frontiersin.org 1 April 2021 | Volume 9 | Article 667815
fcell-09-667815 April 9, 2021 Time: 19:37 # 2
Franco et al. Neurotransmitters and Wholebody Homeostasis Regulators
antigen presentation and T-cell activation, to inflammation.
5-HT, Glu and ATP, taken as regulatory molecules, share
being the endogenous agonists of two types of cell surface
receptors: G protein-coupled receptors (GPCRs) and ionotropic
receptors. These examples provide, in our opinion, a perspective
on the novel opportunities for better understanding the
interrelationships between different organs of the mammalian
body and for better knowledge of the physiopathological
mechanisms of disease. The extracellular effective concentration
of each of these 3 molecules depends on release and uptake, that
may vary from tissue to tissue (and from cell to cell). Addressing
the mechanisms and proteins involved in release/uptake is out
of the scope of the present perspective article. However, it
is worth noting that the therapeutic possibilities of receptors
for ATP, Glu or 5-HT are limited due to the huge variety of
receptors, i.e., by the need of finding highly selective drugs. An
alternative approach is to target the transporters. This approach
was successful in the case of the ProzacR antidepressant drug,
that was approved in 1988 and whose active principle, fluoxetine,
acts as an inhibitor of 5-HT reuptake, mainly at the level
of the presynaptic neuron (Benfield et al., 1986; Fuller, 1986;
Sommi et al., 1987).
GLUTAMATE
As pointed out by Hertz (2006), acceptance by the neurosciences
community of glutamate as the major excitatory transmitter
in the CNS did not come until 1984 (Fonnum, 1984;
Figure 1). Apart from being one of the 20 amino acids in
mammalian proteins, Glu is, directly or indirectly, involved in
the metabolism of all cells in the human body. Transamination
between Glu and alpha-ketoglutarate is the link to the Krebs
cycle, which operates in every cell (erythrocytes are an
exception). Its effects as regulator are mediated by metabotropic
receptors, which are members of the GPCR superfamily
and 3 types of ligand-gated ionotropic channels known
as: N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-
methyl-4-isoxazole propionate (AMPA) and kainate receptors1
(Watkins and Jane, 2006). The function as neurotransmitter is
mainly mediated by ionotropic receptors that, as metabotropic
receptors, are not only expressed in the postsynaptic membrane
but also extrasynaptically and in neural cells other than neurons
(Borroto-Escuela et al., 2018). Among many other possible
examples within the CNS, astrocytes use Glu and glutamine
for glia-neuron communication and it is estimated that 20% of
cerebral glucose consumption is used to provide energy for Glu
metabolism and Glu-mediated actions (Hertz, 2006).
The number of Glu receptors and of receptor combinations
is enormous. Ionotropic receptors are constituted by various
subunits that form homomers or heteromers. The number of
combinations to form functional ligand-gated ion channels is
very high as there are, as of today, 16 human genes coding for
subunits: 7 of NMDA, 4 of AMPA and 5 of kainate receptors.
On top of that, the number of human metabotropic receptors
1https://www.guidetopharmacology.org/
is 8 (mGlu1 to mGlu8, Alexander et al., 2019), and they can
assemble to form homo- or heterodimers, further increasing
the number of possible combinations (Duthey et al., 2002;
Doumazane et al., 2011; Gregory and Goudet, 2021). Consistent
with early regulatory role in Evolution these receptors are not
only found in the nervous system but in cells of every any
mammalian organ/tissue (O’Rourke and Boeckx, 2020). Glu
effects in the periphery are difficult to ascertain due to the
doubts on whether the effects are receptor mediated or metabolic.
The use of pharmacological tools has, however, circumvented
this issue in some cases, for example in the immune system.
On the one hand, metabotropic receptors are key modulators
of events taking place in the so-called immunological synapse.
Dendritic cells release Glu in a non-vesicular manner and
using the Xc− cystine/glutamate antiporter. In the absence of
antigens the expressed Glu receptors impede activation, whereas
after productive antigen presentation, different mGlu receptors
are expressed to enhance T cell proliferation and secretion of
proinflammatory cytokines (Pacheco et al., 2006). On the other
hand, circulating cells of the white lineage express Glu receptors
thus showing that they may respond to the amino acid; resting
and activated lymphocytes plus human cell lines of lymphoid
origin express, at least, mGLu1 and mGlu5 receptors (Pacheco
et al., 2004). It is an open question whether blood Glu levels are
important in the control of immune function or it is required a
particular environment of cell-to-cell communication in which
Glu is released to act locally. Thus, it is unlikely that Glu acts
in endocrine fashion. Reviews on Glu role of the physiology of
dendritic and T cells are found elsewhere (Pacheco et al., 2007,
2009). Nicoletti et al. (2007) provided an authoritative review
on Glu receptor involvement in other non-neural systems and
in cancer. In fact, recent work has focused on the facilitation
in cancer progression by ionotropic Glu receptors, that arise as
targets to manage and refine anti-cancer management (Stepulak
et al., 2014; Ribeiro et al., 2017; Ma et al., 2020).
Glu receptor-based therapeutic strategies will require, first,
identifying the most convenient target in each disease and,
second, the development of highly selective drugs or of
allosteric modulators (Nicoletti et al., 2011; Ahmed et al., 2020;
Qu et al., 2021).
ATP
This part of the article is dedicated to the discoverer of purinergic
nerves, Prof. Geoffrey Burnstock, who was a fine and inspiring
scientist (Hoffmann et al., 2020; Abbracchio, 2021; Franco, 2021).
ATP may be released by different cells, including peripheral
and central neurons (see Burnstock, 2007 and references
therein). Neither identification of ATP as neurotransmitter nor
convincing colleagues of this fact (storage in vesicles, release
to the synaptic cleft after challenge, etc.) was an easy task. An
historical perspective from discovery to the state of the art
in 2014 is found in Burnstock (2014). Similar to Glu, ATP
is involved in metabolism; actually, ATP is key for life on
Earth. Probably for this reason Evolution selected ATP levels
as a snitch for homeostasis. The drop in ATP levels would
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FIGURE 1 | Scheme of some actions of Glu and ATP in the nervous system.
be considered an emergency signal. As for Glu, ATP was first
detected as a neurotransmitter to later being found in many
systems and is now considered a holistic regulator of whole-
body homeostasis. As a neurotransmitter it has a key role in
the peripheral nervous system and cumulative evidence points
to a key role in visceral pain; Burnstock wrote in 2016 a
review that “describes purinergic mechanosensory transduction
involved in visceral, cutaneous, and musculoskeletal nociception
and on the roles played by receptor subtypes in neuropathic and
inflammatory pain” (Burnstock, 2016). ATP is also involved in
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pain derived from cancer via P2X receptors (Wen-Jun et al., 2020;
Zhang et al., 2020).
Not as high as for Glu receptors but the number of so-called
purinergic receptors, that respond to ATP but also to ADP and
pyrimidine nucleotides, is very high. Ionotropic receptors are
known as P2X and GPCRs are denoted as P2Y (Figure 1). From
X-ray crystallography it is deduced that ionotropic receptors are
either homotrimers or heterotrimers, and 7 are the subunits so far
discovered (P2X1 to P2X7). Soon after the cloning of the genes for
P2Y receptors and of subunits of P2X receptors, it was clear that
extracellular ATP was not only acting as neurotransmitter (Illes
et al., 2020; Jacobson et al., 2020). Actually, much of its action is
mediated by receptors located in different cells and in different
cell locations, e.g., not only in the myocyte membrane part of the
neuromuscular junction and not only in smooth muscle cells but
also in lymphocytes (see below), the kidney (Vallon et al., 2020),
the lung (Wirsching et al., 2020), etc.
As for Glu, and for similar reasons, it is considered that
ATP as regulator acts in microenvironments in which close
cell-to-cell communication occurs. ATP action in the CNS is
important, not necessarily due to neurotransmission mechanisms
but via activation by ATP on the multiple P2X and P2Y receptors
that are expressed in neural cells. An excellent account of the
purinergic action in the brain was probably one of the last
papers of Burnstock (2020). Again, the immune system appears
as the target of many studies devoted to the role of nucleotides
acting via P2X and P2Y receptors. The laboratory of F. di
Virgilio has contributed to significantly increase the knowledge
on the role of P2 receptors in the control of the immune system
function; indeed other laboratories have also contributed (see
Rayah et al., 2012; Di Virgilio et al., 2017, and references therein).
The P2X7 receptor is attracting attention in the last decade for
its potential as target in some diseases. Surely, P2X7 receptor
is involved in regulating infection and inflammation but there
is controversy as how to pharmacologically address its potential
to make it provide antiinflammatory actions (Di Virgilio et al.,
2017; Savio et al., 2018). We would like to add that purinergic
signaling is relevant in a prevalent disease for which there are
few therapeutic opportunities, namely intestinal inflammation
(Longhi et al., 2017).
The section cannot be complete without presenting P1
receptors; there are four (A1, A2A, A2B, and A3) all belonging
to the GPCR superfamily (Figure 1). Virtually all extracellular
ATP is broken down by various nucleotidases to produce
adenosine, which is the endogenous agonist of purinergic P1
receptors. Thus, all the regulatory action triggered by ATP is later
followed by adenosine receptor-mediated signaling. Adenosine
is not considered a neurotransmitter but a neuromodulator.
P1 receptors are found in almost any neural cell and also in
virtually any peripheral cell in the human body. Importantly,
cardiovascular actions of the compound were detected in the
twenties (past century) and about 30 years later it was suggested
as potential drug to combat tachycardias. Adenosine in bolus
administration was approved for the treatment administered with
great success to critically ill patients suffering from paroxysmal
tachycardia (Drury and Szent-Györgyi, 1929; Wolf and Berne,
1956; Buckley et al., 1959). Further drugs targeting P1 receptors
have not been approved as quickly as those targeting adrenergic
(beta-blockers) and histamine (H2 antagonists) receptors. P1
receptor antagonist are considered as generally safe. Then natural
compounds, caffeine and theophylline, which are non-selective
antagonists of these receptors, are approved for human use
(Franco, 2009; Franco et al., 2013; Oñatibia-Astibia et al., 2016,
2017), and more recently, an antagonist of the A2A receptor,
istradefylline (Mizuno and Kondo, 2013; Kondo et al., 2015),
has been approved (in Japan and United States) for adjuvant
therapy in Parkinson’s disease. In addition, there are good
prospects for P1 receptor ligands to make more effective the
immune-based anti-cancer therapy (Ohta and Sitkovsky, 2011;
Hatfield and Sitkovsky, 2016; Fong et al., 2020; Sitkovsky, 2020;
Willingham et al., 2020).
Finally, we would like to end this section with the very
interesting discovery of purinergic (both P1 and P2) receptor
involvement in acupuncture-mediated health benefits. To our
knowledge the first ATP/acupuncture link was established by
Smith and Kenyon (1973) and the first adenosine/acupuncture
links were established by Liu et al. (1994a,b). Acupuncture leads
to the release of ATP that acts on P2 receptors to produce, among
other, analgesia (Burnstock, 2013; Tang et al., 2016, 2019; Tang
and Illes, 2020). The subsequent conversion of ATP to adenosine
leads to the participation of proximally located P1 receptors
(Trento et al., 2021). In summary, there is consensus in that a
significant number of acupuncture interventions leads to ATP
release to the extracellular milieu and P2 (and P1) engagement.
SEROTONIN
5-HT (or serotonin) is known for being one of the main
neurotransmitters in the nervous system of mammals; it plays
a crucial role as modulator of essential elements of our
daily life such as mood, sleep, social behaviors, learning and
appetite (Barnes and Sharp, 1999; Gingrich and Hen, 2001;
Canli and Lesch, 2007). Although serotonin is best known for
regulating higher functions, it is also key in maintaining whole
body homeostasis.
While there is a tendency to describe 5-HT as a brain-based
and derived molecule, the 95% of the 5-HT is synthetized,
stored and released into the gut. This is mainly accomplished
by the enterochromaffin cells (Gershon et al., 1965; Costedio
et al., 2007; Gershon and Tack, 2007), which are capable of
synthetizing it from L-tryptophan by the action of the tryptophan
hydroxylase (TPH, Yu et al., 1999). The role of 5-HT in the
correct functionality of the gut is a controverted theme, as it
is reported that 5-HT modulates gut peristalsis, secretion and
motility (Gershon and Tack, 2007), whereas other studies using
TPH1 knockout mice, which are unable to synthetize 5-HT, show
no alteration of intestinal motility (Li et al., 2011). Nonetheless,
it is suggested that serotonin receptors may be targets to combat
irritable bowel syndrome (Gershon and Tack, 2007).
There is evidence of a link between the gut and the brain that
is somehow mediated by 5-HT (Hooper et al., 2012; Carabotti
et al., 2015). This has also been demonstrated for dopamine
and it is a hot topic in relationship with Parkinson’s disease
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(see Franco et al., 2021 for recent review). Among the most
likely mechanisms of intercommunication, cells of the immune
system may be mediators that respond to 5-HT due to the
expression of some of its receptors. It is known that different
cell types of the innate immune system, including dendritic cells
(O’Connell et al., 2006), monocytes (Finocchiaro et al., 1988)
and mastocytes (Tamir et al., 1982) express components of the
serotoninergic machinery, e.g., TPH, serotonin transporters and
serotonin receptors. Accordingly, it is possible to generate 5-
HT and/or to respond to it. A similar trend is found in the
adaptive immune system in cells such as T and B lymphocytes
(Gordon and Barnes, 2003). Actually, almost any blood cell,
except erythrocytes, expresses enzymes related to 5-HT handling
and transport, and serotonin receptors. Overall it is assumed
that the compound regulates from inflammation to chemotaxis
(Pfeiffer et al., 1985; Konig et al., 1994).
5-HT action depends on the cell type and, eventually, in the
activation state, for instance in resting versus activated blood
cells. On the one hand, 5-HT enhances the production of IFN-
γ by human NK cells (Hellstrand et al., 1993) and alters the
amount of cytokines released by dendritic cells in such a way
that the release of TNF-α and IL-6 is decreased while that of
IL-1β and IL-8 is increased (Idzko et al., 2004). On the other
hand, in macrophages, 5-HT reduces LPS-induced release of
pro-inflammatory cytokines also skewing macrophages to the
anti-inflammatory M2 phenotype. The involved receptors are 5-
HT2B and 5-HT7 (Quintero-Villegas and Valdés-Ferrer, 2019).
Furthermore, the use of a 5-HT7 receptor agonist in experimental
sepsis reduces the plasma levels of IL-6, IL-1β, and of lung NFκB,
thus reducing the death rate (Cadirci et al., 2013). However,
there are scenarios in which 5-HT potentiates inflammation via
other receptors, namely serotonin 5-HT3 and 5-HT4 receptors
(Salaga et al., 2019). The different capacity to modulate cytokine
production in opposite outcomes shows that serotoninergic
action is receptor and tissue-specific.
Probably the first hints of the regulatory role of 5-
HT in inflammation came from evidence of alterations on
both immune function and serotoninergic signaling in some
psychiatric disorders. Although the 5-HT blood levels have not
real diagnostic value, they serve to establish some interesting
correlations. Onore et al. (2012) documented alterations in
immune function in subjects with autism spectrum disorder that
correlated with high blood 5-HT levels (Veenstra-Vanderweele
and Blakely, 2012). Correlations between depression and
alterations in both immune and serotonergic systems are
widely reported in the literature. Levels of pro-inflammatory
cytokines such as IL-6 and IFN-γ from T-cells and IL-β1 and
TNF-α from the cells of the innate immune system correlate
with depression (Raison et al., 2009; Rybka et al., 2016).
Also, there is a correlation between risk of depressive moods
and single nucleotide polymorphisms found in inflammatory
genes crucial for T-cell function. There is even evidence
postulating that antidepressant medication can have anti-
inflammatory action. For example selective 5-HT reuptake
inhibitors, which are used as antidepressants, are reported to
reduce and normalize cytokine levels in depressed patients
(Basterzi et al., 2005).
SARS-CoV-2 infection leads to COVID-19 that consists of 3
phases that are not manifested in all patients: asymptomatic or
low-asymptomatic phase, mildly asymptomatic phase and severe
phase (Ayres, 2020). In addition, neurological post-COVID-
19 alterations are unexpected side effects of unknown causes
and coursing without any defined trend. In psychiatric patients
these potential neurological manifestations may aggravate their
status. Stressful and anxious conditions may be responsible,
at least in part, of post-COVID-19 side effects (Salleh, 2008;
Jones and Thomsen, 2013); an increase of IL-6 may also impact
in the severity of depression (Zorrilla et al., 2001). In the
most severe cases, one of the most harmful events is a robust
inflammation with a cytokine release syndrome that may lead
to 10-, 100-, and even 1,000-fold increase in the reference blood
levels of IL-1β, IL-6, and TNF-α (Chatenoud, 1989). About
40% of the patients treated in the critical care unit display an
acute respiratory distress syndrome associated with pneumonia
(Guan et al., 2020). In summary, COVID-19 may lead to
overstimulation of the immune system (Giamarellos-Bourboulis
et al., 2020) and it has been suggested that inhibition of serotonin
reuptake may reduce exacerbated inflammation (Hamed and
Hagag, 2020). Remarkably, this hypothesis has been supported
by a recent study reporting less risk of intubation or death in
patients taking antidepressant medication (Hoertel et al., 2021).
Inhibitors of 5-HT reuptake could be a novel and effective
treatment for severe COVID-19 cases as they could ameliorate
the cytokine release syndrome thanks to their capacity to reduce
the levels of pro-inflammatory cytokines. For example, these
compounds significantly increase oxygen saturation in patients
with severe chronic obstructive pulmonary disease (Perna et al.,
2004). At the level of speculation, the compounds may act
by both reducing inflammation and the levels of anxiety and
stress of COVID-19 patients. Data from research with other
viruses show that inhibiting serotonin uptake has antiviral
properties by downregulating (in lymphocytes) the expression
of HIV receptor and coreceptor (Greeson et al., 2016) or by
reducing viral replication of Coxsackevirus B4 (Alidjinou et al.,
2015). Indeed pancreatic infection with this virus is completely
abolished by the widely used 5-HT reuptake inhibitor, fluoxetine
(Alidjinou et al., 2015).
Although 5-HT is normally known as a neurotransmitter, it
is undeniable that its acts as a holistic modulator in virtually
all organs and cell types. It is assumed that every cell in the
mammalian body expresses one (or more) of the reported
serotonin receptors (14 in total): 5-HT1A, 5-HT1B, 5-HT1D,
5-HT1E, 5-HT1F , 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT4, 5-
HT5A, 5-HT5B, 5-HT6, and 5-HT7 (Barnes et al., 2021). Except
the 5-HT3, which is an ionotropic receptor, the others belong to
the GPCR superfamily; Gi is the canonical G protein of the 1 and
5A types, Gs is the canonical G protein of 4 and 6 receptor types,
and members of the 2 type preferentially couple to Gq. There are
many unknowns due to the large number of receptors and the
potentially different signaling pathways triggered by serotonin
receptor activation, but any new scientific achievement will be
extremely useful to understand 5-HT action and to identify
further serotonin-related targets (transporters or receptors) to
combat a variety of diseases.
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